SOLIAIR

Company Overview

Snapshot

Founded in August 2012 by Solomon Jacob, SOLIAIR operated with 1–10 employees. The company received funding across one disclosed round from one investor. In November 2013, SOLIAIR announced a new drug discovery for respiratory and lung diseases.

Business overview

SOLIAIR is an Israeli alternative medicine company focused on developing natural supplements for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory disorders. The company's core technology involves a mixture of plant extracts, including ginseng, ginkgo, and various antioxidants. SOLIAIR aims to market and sell private-label naturopathic and homeopathic dietary supplements, serving both B2B and B2C markets globally, with a focus on Europe, the United States, Canada, Asia, and Israel.

Strategic signal

In November 2013, SOLIAIR announced a new drug discovery for respiratory and lung diseases. This development signaled the company's early potential in addressing chronic conditions through alternative medicine, indicating a strategic focus on novel ingredient formulations within the biopharmaceutical and herbal medicine sectors.

Company Intelligence Q&A

What is SOLIAIR's primary focus?

SOLIAIR is an alternative medicine company specializing in natural supplements for treating chronic obstructive pulmonary disease (COPD) and other respiratory disorders.

When was SOLIAIR founded?

SOLIAIR was founded in August 2012.

Who founded SOLIAIR?

SOLIAIR was founded by Solomon Jacob.

What was a key product development announced by SOLIAIR?

In November 2013, SOLIAIR announced a new drug discovery targeting respiratory and lung diseases.

What is the current status of SOLIAIR?

SOLIAIR is currently non-active and ceased to operate in July 2021.